Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY1 | Q08828 | 15/20 | 0.71 |
| ▸ | ADCY8 | P40145 | 13/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | HTR2B | P41595 | 2/20 | 0.60 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20673008 | 0.90 | ADCY1 (0.72) | ADCY1ADCY8KDM4EALDH1A1HTR2B | |
| SCHEMBL20673002 | 0.88 | ADCY1 (0.78) | ADCY1ADCY8KDM4EALDH1A1HTR2B | |
| SCHEMBL20673006 | 0.86 | ADCY1 (0.73) | ADCY1ADCY8KDM4EALDH1A1HTR2B | |
| SCHEMBL20673244 | 0.84 | ADCY1 (0.58) | ADCY1ADCY8KDM4EALDH1A1HTR2B | |
| SCHEMBL20673005 | 0.84 | ADCY1 (0.60) | ADCY1ADCY8KDM4EALDH1A1HTR2B | |
| SCHEMBL20673009 | 0.84 | ADCY1 (0.73) | ADCY1ADCY8HTR2BSLC2A1 | |
| SCHEMBL20673090 | 0.83 | ADCY1 (1.00) | ADCY1ADCY8HTR2B | |
| SCHEMBL20673129 | 0.82 | ADCY1 (0.85) | ADCY1ADCY8HTR2BSLC2A1 | |
| SCHEMBL20672977 | 0.82 | ADCY1 (0.69) | ADCY1ADCY8KDM4EALDH1A1HTR2B | |
| SCHEMBL20673082 | 0.79 | KDM4E (0.59) | ADCY1ADCY8KDM4EALDH1A1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667623-B2 | Scaffold of adenylyl cyclase inhibitors for chronic pain and opioid dependence | PURDUE RESEARCH FOUNDATION (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667623-B2 | Scaffold of adenylyl cyclase inhibitors for chronic pain and opioid dependence | PURDUE RESEARCH FOUNDATION (US) | 2023-06-06 | — | — | US | disclosed |
| US-20200239447-A1 | NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE | PURDUE RESEARCH FOUNDATION (US) | 2020-07-30 | — | — | US | disclosed |
| US-10662176-B2 | Scaffold of adenylyl cyclase inhibitors for chronic pain and opioid dependence | PURDUE RESEARCH FOUNDATION (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190023688-A1 | NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE | PURDUE RESEARCH FOUNDATION (US) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239447-A1 | NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE | CAP1, ADCY1, ADCYAP1R1 | ADCY1 2/4885ADCY8 7/4885KDM4E 2744/4885 |
| US-20190023688-A1 | NOVEL SCAFFOLD OF ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE | CAP1, ADCY1, ADCYAP1R1 | ADCY1 2/4885ADCY8 7/4885KDM4E 2744/4885 |
| US-11667623-B2 | Scaffold of adenylyl cyclase inhibitors for chronic pain and opioid dependence | CAP1, ADCY1, ADCYAP1R1 | ADCY1 2/4885ADCY8 11/4885KDM4E 2458/4885 |
| US-10662176-B2 | Scaffold of adenylyl cyclase inhibitors for chronic pain and opioid dependence | CAP1, ADCY1, ADCYAP1R1 | ADCY1 2/4885ADCY8 11/4885KDM4E 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.